Datasets:
ickma
/
sec_AA

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
198
2.89k
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or becomes unexercisable without having been exercised in full, is surrendered pursuant to an exchange program, or, with respect to restricted stock, restricted stock units, performance units or per...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Plan, respectively. The following table summarizes the stock option activity during the year ended December 31, 2022: Shares Weighted AverageExercise Price Weighted AverageRemaining Contractual ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 2022 722,198 18.53 6.84 2,251 Vested and expected to vest as of December 31, 2022 2,990,423 19.28 8.59 2,849 As of December 31, 2022, the aggregate intrinsic value of options outstanding w...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of 2.7 years. 143 Table of Contents The total intrinsic value of the options exercised during the years ended December 31, 2022 and 2021 was $1.3 million and $1.0 million, respectively. As of De...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. ,310 657 Total 9,643 2,106 Included in the year ended December 31, 2021 is $0.3 million of expense related to the acceleration of vesting associated with individual awards assumed in the Merger....
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. determine the estimated fair value for share-based awards. Option pricing and models require the input of various assumptions, including the option’s expected life, expected dividend yield, price vo...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 3 Expected dividend yield Aadi Bioscience, Inc. determines the assumptions used in the option pricing model in the following manner: Risk-Free Interest Rate For the determination of the risk-free...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its share-based awards. Aadi Bioscience, Inc. will continue to apply this process un...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. estimate the expected term. Prior to the Company’s Merger, given the absence of a public trading market for the Company’s common stock, its board of directors exercised their judgment and considere...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as rece...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. Warrants to Purchase Common Stock Aadi Bioscience, Inc. had ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. October 24, 2024. During the year ended December 31, 2022, 7,500 warrants were exercised. At the grant date, the fair value of these awards was determined using a Black-Scholes option pricing model....
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. price volatility and risk-free interest rate of the underlying stock. The calculation was based on the following assumptions: Year EndedDecember 31, 2022 Strike price (per share) $11.40 - $11.66...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. will be recognized over six months. No liability was outstanding as of December 31, 2021. During the years ended December 31, 2022 and 2021 , 27,202 and zero shares were issued under the 2021 ES...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. federal benefit 1.8 0.5 Nondeductible interest (0.1) Other permanent items (0.1) 0.4 Officers Compensation (1.7) Nondeductible impairment (13.8) Research credit 2.4 0.9 Change in valu...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 5,417 Other 4,219 1,214 Total deferred tax assets 53,352 39,174 Valuation allowance (52,766) (38,410) Total gross deferred tax assets, net of valuation allowance 586 764 Deferred tax l...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. to the amount expected to be realized in future periods. Aadi Bioscience, Inc. has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. state NOL carryforwards begin to expire in 2030 and 2037 unless previously utilized. Aadi Bioscience, Inc. also has federal and state research credit carryforwards of approximately $5.0 million and...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of the Internal Revenue Code (“IRC”), utilization of the Company’s NOL carryforwards and R&D credits may be subject to annual limitations in the event of any significant future changes in its owners...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. the facts and circumstances that exist at each reporting period. Subsequent changes in judgement based upon new information may lead to changes in recognition, derecognition, and measurement. Adjust...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Decrease related to prior year positions (24) Increase related to current year positions 704 294 Balance at the end of year 3,380 2,674 Due to the existence of the valuation allowance, future...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. no accrued interest and no penalties related to income tax matters in the Company’s balance sheet as of December 31, 2022 and has not recognized interest or penalties in the Company’s statement of o...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 2, the Company has not recorded any material adjustments to its income tax provision related to the provisions with the CARES Act. Aadi Bioscience, Inc. will continue to analyze the impact that the C...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Company. In the Request for Arbitration, EOC claims that the Company breached certain provisions of the EOC License Agreement, including failing to provide certain manufacturing and clinical develop...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. contracts are generally cancellable, with notice, at the Company’s option. Aadi Bioscience, Inc. recorded accrued expenses of $2.8 million and $4.8 million in its consolidated balance sheet for expe...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. agreement with Mirati Therapeutics, Inc. (“Mirati”) to evaluate the combination of Mirati’s adagrasib, a KRASG12C selective inhibitor, and FYARRO in KRAS G12C mutant non-small cell lung cancer (NSCL...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. . In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and FYARRO in combination in patients both with and without prior exposure to a KRASG12C inhibitor. The tr...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. entry date, as defined by the 401k Plan document, following the employment date. Each employee can contribute a percentage of compensation up to a maximum of the statutory limits per year. Company ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Interim Chief Executive Officer and President, and Chief Financial Officer, to allow...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2022 . Based on that evaluation, our Interim Chief Ex...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. external purposes in accordance with U.S. generally accepted accounting principles. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fa...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. of the effectiveness, as of December 31, 2022 , of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponso...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. control over financial reporting. Item 9B. Other Information. None. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not applicable. 149 Table of Contents Part III...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. is located at www.aadibio.com. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website, or in a current report on Form 8-K as may be required by law. Am...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and the submission of proposals for consideration at meetings of stockholders, including by adding a requirement that a stockholder seeking to nominate director(s) at a meeting of stockholders deliv...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. entirety by reference to the Amended and Restated Bylaws, a copy of which was filed as Exhibit 3.1 to our Form 8-K filed on December 7, 2022 and is incorporated herein by reference. Item 11. Execut...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. is incorporated herein by reference. Item 14. Principal Accounting Fees and Services The information required by this Item 14 will be contained in the Definitive Proxy Statement and is incorporate...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. signature page of this Annual Report. The Exhibit Index is incorporated herein by reference. Exhibit Index ExhibitNumber Description 2.1 Agreement and Plan of Merger, dated May 16, 2021, by and...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Form 8-K (File No. 001-38560) filed with the SEC on August 27, 2021). 3.2 Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 2). 10.1 Form of Securities Purchase Agreement, dated September 22, 2022, by and among the Company and the Purchasers (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report o...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Registration Rights Agreement dated August 26, 2021, by and between Aadi Bioscience, Inc. (formerly known as Aerpio Pharmaceuticals, Inc.) and certain purchasers listed therein (incorporated by refer...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Giacobello. 10.6# Aadi Bioscience, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K (File No. 001-38560) filed with the SEC...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K (File No. 001-38560) filed with the SEC on August 27, 2021). 151 Table of Contents 10.9# Aadi Bioscience, ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. (incorporated by reference to Exhibit 10.10 to the Registrant’s Current Report on Form 8-K (File No. 001-38560) filed with the SEC on August 27, 2021). 10.11# Form of Indemnification Agreement bet...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 2019 (incorporated by reference to Exhibit 10.13 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38560) filed with the SEC on November 10, 2021). 10.14+ Amendment No. 1 to the Amen...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. between BRE Sunset Coast, LLC and Aadi Bioscience, Inc. 10.16 First Amendment to Office Lease dated August 30, 2021 by and between BRE Sunset Coast, LLC and Aadi Bioscience, Inc. (incorporated by ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and Aadi Bioscience, Inc. (incorporated by reference to Exhibit 10.17 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38560) filed with the SEC on November 10, 2021). 10.19# Senior...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Fresenius Kabi, LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38560) filed with the SEC on September 20, 2021). 10.21*+ Amendment No.1...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. .1 to the Registrant’s Current Report on Form 8-K (File No. 001-38560) filed with the SEC on March 17, 2022). 21.1* List of Subsidiaries of the Company 23.1* Consent of BDO USA LLP 31* Certific...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS IXBRL Inline Instance Document 101.SCH IXBRL Inline Taxonomy Extension Schema Document 101.CAL IXBRL Inline Taxonomy Extensio...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. furnished, not filed, with this report #    Indicates a management contract or any compensatory plan, contract or arrangement. +    Portions of this exhibit have been omitted pursuant to Item 601(...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. AADI BIOSCIENCE, INC. Date: March 28, 2023 By: /s/ Scott Giacobello Scott Giacobello Interim Chief Executive Officer and President, and Chief Financial Officer(Principal Executive Officer) PO...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing req...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Giacobello Interim Chief Executive Officer and President, and Chief Financial Officer(Principal Executive, Financial and Accounting Officer) March 28, 2023 Scott Giacobello /s/ Caley Castelein ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Hehenberger Director March 28, 2023 Karin Hehenberger, M.D., Ph.D. /s/ Richard Maroun Director March 28, 2023 Richard Maroun, J.D. /s/ Emma Reeve Director March 28, 2023 Emma Reeve 154 ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) QUAR...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. ______________________________________ Delaware 61-1547850 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 17383 Sunset Boulevard Suite A250Paci...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that th...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “s...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No As of May 5, 2023, the registrant had 24,436,990 shares of common stock, $0.0001 par value per share, outstanding. Table ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. – Three Months Ended March 31, 2023 and 2022 (Unaudited) Condensed Consolidated Statements of Cash Flows – Three Months Ended March 31, 2023 and 2022 (Unaudited) Notes to Condensed Consolidated F...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 3. Defaults Upon Senior Securities 99 Item 4. Mine Safety Disclosures 99 Item 5. Other Information 99 Item 6. Exhibits 100 Signatures 101 Table of Contents PART I—FINANCIAL INFORMATION...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 3,803 1,861 Prepaid expenses and other current assets 4,388 3,746 Total current assets 164,930 180,029 Property and equipment, net 2,225 508 Operating lease right-of-use assets 1,437 1,5...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 1,267 Due to licensor (Note 8) 5,757 5,757 Total liabilities 24,668 25,859 Commitments and contingencies (Note 13) Stockholders’ equity: Preferred stock, $0.0001 par value, 10,000,000 shares...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 361,689 Accumulated other comprehensive loss (32) (115) Accumulated deficit (218,421) (203,198) Total stockholders’ equity 145,986 158,378 Total liabilities and stockholders’ equity 170,65...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Selling, general and administrative 11,207 9,148 Research and development 10,956 6,794 Cost of goods sold 529 179 Total operating expenses 22,692 16,121 Loss from operations (16,825) ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. diluted (0.57) (0.66) Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted 26,862,646 20,914,842 The...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 435 361,689 (115) (203,198) 158,378 Share-based compensation expense 2,740 2,740 Issuance of common stock upon exercise of stock options Other comprehensive income 83 83 Net loss (15,223...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 089 (142,685) 136,406 Share-based compensation expense 1,781 1,781 Issuance of common stock upon exercise of warrants 54 54 Issuance of common stock upon exercise of stock options 40 244 ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. operating activities: Net loss (15,223) (13,857) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation expense 2,740 1,781 Discount amortizatio...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. liabilities (1,544) (4,129) Net cash used in operating activities (21,310) (19,415) Cash flows from investing activities: Purchases of property and equipment (1,369) (23) Purchase of short...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. equivalents and restricted cash at beginning of year 39,083 148,989 Cash, cash equivalents and restricted cash, end of period 34,110 129,849 Supplemental disclosure of cash flow information: ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. or “Aadi”) is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Aadi’s lead drug prod...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. ). On February 22, 2022, Aadi launched FYARRO in the United States for treatment of advanced malignant PEComa. FYARRO is licensed to Aadi by Abraxis BioScience, LLC, a wholly owned subsidiary of Ce...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. capital and providing general and administrative support for these operations and has only recently begun to realize revenues from its planned principal operations commencing with the commercial sal...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. cash, cash equivalents and short-term investments of $151.2 million at March 31, 2023. Management believes the Company’s current cash, cash equivalents and short-term investments will provide suffi...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. and Company, LLC (“Cowen”), pursuant to which the Company may offer and sell, from time to time at the Company’s sole discretion, shares of its common stock having an aggregate offering price of up ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. equity and cash flows for each period presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“A...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 2, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2023. Table of Contents Comprehensive Loss Comprehensive loss is defined as the change in equity d...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. operations and manages its business in one operating segment, which is the business of developing and commercializing proprietary therapeutics. All the assets and operations of the Company’s sole op...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. s, share-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the fut...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. recent failure of Silicon Valley Bank, at which the Company holds cash and cash equivalents in multiple accounts, exposed the Company to credit risk prior to the resolution by the Federal Deposit In...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. that may affect customers’ ability to pay. Customer Concentration The majority of the Company's revenue for the three months ended March 31, 2023 were from two customers at 51% and 48% of the Comp...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. .0 million, respectively. Restricted cash consists of a letter of credit secured by restricted cash in connection with one of the Company's office leases described in Note 7, and is included in other...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would b...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions which reflect those that a market participant would use Financial ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. fair value measurements, the Company applies valuation techniques deemed the most appropriate under the GAAP guidance based on the nature of the assets and liabilities being measured. The carrying ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. interest income are recognized when earned. Aadi Bioscience, Inc. recognizes purchase premiums and discounts as interest income using the interest method over the terms of the securities. Realized g...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. not that the Company will be required to sell the securities before the recovery of amortized cost. Aadi Bioscience, Inc. records changes in allowance for expected credit loss in other income (expen...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. contracts. As of March 31, 2023 and December 31, 2022, recorded customer allowances for charge backs were $0.8 million and $0.1 million, respectively. There were no allowances for credit losses and ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. expensed. Details of inventory are presented as follows (in thousands): March 31, 2023 December 31, 2022 Raw materials 2,911 944 Work in process Finished goods 892 917 Total 3,803 1,861...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 3 December 31, 2022 Computers and Software 366 338 Construction in process 1,805 77 Furniture and fixtures 65 65 Leasehold improvements 129 129 Total 2,365 609 Accumulated depreciati...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Aadi Bioscience, Inc. does not recognize assets or liabilities f...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. ) the title to the underlying asset transfers at the end of the lease term, or (v) if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lesso...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate Table of Contents incremental borrowing rate, determined ...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. Aadi Bioscience, Inc. has elected the practical expedient to not sepa...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. 3 and December 31, 2022 Revenue Recognition and Related Allowances Aadi Bioscience, Inc. recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflec...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer....
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. SDs”) and a specialty pharmacy (“SP”). Aadi Bioscience, Inc. recognizes product sales when the SDs and SP obtain control of the product. Product sales are recorded at the net sales price, which inclu...
YOU are a financial analyst. You are reading a report of a company. The report is about the company's financial status. are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or statutory requirements. The allowance for rebates is based on co...